1-14 of 14
Lars Møller Pedersen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Miro Nylén, Leo Meriranta, Emil Hiitola, Maare Arffman, Harald Holte, Judit Mészáros Joergensen, Peter Brown, Sirkku Jyrkkiö, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Lars Møller Pedersen, Mikael Eriksson, Satu Mustjoki, Sirpa Leppä, Mikko Myllymäki
Journal: Blood
Blood (2024) 144 (Supplement 1): 1601.
https://doi.org/10.1182/blood-2024-201928
Published: 2024
Journal Articles

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Gilles Andre Salles, MD PhD, John Francis Seymour, MBBS, Pierre Feugier, MD, Fritz Offner, MDhD, Armando Lopez-Guillermo, David Belada, MD PhD, Luc Xerri, MD PhD, Reda Bouabdallah, MD, John Catalano, Pauline Brice, MD, Corinne Haioun, Alejandro Martín, MD PhD, Lars Moller Pedersen, Alain Jacques Delmer, MD, David Simpson, MBChB, Sirpa Leppa, MD, Pierre Soubeyran, MD PhD, Rene-Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Vincent Ribrag, Maria Gomes Silva, Emmanuelle Nicolas-Virelizier, MD, Thomas Lister, MD, Jane Estell, Gustavo Milone, MD, Anne Sonet, MD, Julie Assemat, Harald Zeuner, Bertrand Coiffier, MD PhD, Herve Tilly
Journal: Blood
Blood (2017) 130 (Supplement 1): 486.
https://doi.org/10.1182/blood.V130.Suppl_1.486.486
Published: 2017
Journal Articles

Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Karin Fjordén, MD, Frida Pauly, PhD, Sirpa Leppä, MD PhD, Harald Holte, MD PhD, Magnus Björkholm, MD PhD, Oystein Fluge, MD PhD, Lars Möller Pedersen, MD PhD, Mikael Eriksson, MD PhD, Anna Isinger-Ekstrand, PhD, Carl Borrebaeck, PhD, Mats Jerkeman, MD PhD, Christer Wingren, PhD
Journal: Blood
Blood (2014) 124 (21): 1618.
https://doi.org/10.1182/blood.V124.21.1618.1618
Published: 2014
Journal Articles

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Clinical Trials & Observations
Clémentine Sarkozy, John Francis Seymour, Christophe Ferme, Dolores Caballero, Hervé Ghesquieres, Sirpa Leppa, Richard Delarue, Lars Moller Pedersen, Christiane Mounier, Maria Gomes Da Silva, Catherine Chassagne-Clement, Marie Maerevoet, Gilles Salles
Journal: Blood
Blood (2014) 123 (17): 2740–2742.
https://doi.org/10.1182/blood-2014-02-553693
Published: 2014
Journal Articles

Real World Data On Primary Treatment For Mantle Cell Lymphoma 2000-2011 – a Nordic Lymphoma Group Observational Study

Anna Abrahamsson, Alexandra Albertsson Lindblad, Peter de Nully Brown, MD, Stefanie Baumgartner Wennerholm, Lars Moller Pedersen, Francesco d'Amore, Herman Nilsson-Ehle, Paw Jensen, Michael Pedersen, Christian H. Geisler, Mats Jerkeman
Journal: Blood
Blood (2013) 122 (21): 4358.
https://doi.org/10.1182/blood.V122.21.4358.4358
Published: 2013
Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Gilles Andre Salles, MD, PhD, John Francis Seymour, MBBS, FRACP, PhD, Pierre Feugier, MD, PhD, Fritz Offner, MD, Armando Lopez-Guillermo, MD, PhD, David Belada, M.D., Ph.D., Luc Xerri, MD, PhD, Reda Bouabdallah, MD, John Catalano, MBBS FRACP FRCPA, Brice Pauline, MD, Dolores Caballero, MD, PhD, Corinne Haioun, MD, PhD, Lars Moller Pedersen, Alain Delmer, MD, David Simpson, Sirpa Leppa, Pierre Soubeyran, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Christophe Ferme, MD, Maria Gomes da Silva, Catherine Sebban, MD, Andrew Lister, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, Anne Sonet, MD, Bertrand Coiffier, MD, PhD, Herve Tilly, MD
Journal: Blood
Blood (2013) 122 (21): 509.
https://doi.org/10.1182/blood.V122.21.509.509
Published: 2013
Journal Articles

Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Karen Juul Mylam, Tarec Christoffer El-Galaly, Peter de Nully Brown, Bodil Himmelstrup, Dorte Gillstrøm, Ida Blok Sillesen, Lars Munksgaard, Bjarne Bach Pedersen, Ilse Christiansen, Paw Jensen, Anne Lerberg Nielsen, Lars Møller Pedersen
Journal: Blood
Blood (2012) 120 (21): 2646.
https://doi.org/10.1182/blood.V120.21.2646.2646
Published: 2012
Journal Articles

A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO

Anne Ortved Gang, Michael Pedersen, MD, Francesco d'Amore, Lars Møller-Pedersen, MD, PhD, Bo Amdi Pedersen, Paw Jensen, Bjarne Bach Pedersen, Michael B. Møller, MD, DMSc, Ole Gadeberg, Steen Ingeberg, Torben mourits-Andersen, MD, Stanislaw Pulczynski, Tobias Wirenfeldt Klausen, Peter De Nully Brown
Journal: Blood
Blood (2012) 120 (21): 3651.
https://doi.org/10.1182/blood.V120.21.3651.3651
Published: 2012
Journal Articles

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

Satu Koivula, Minna Taskinen, Ping Chen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sampsa Hautaniemi, Sirpa Leppa
Journal: Blood
Blood (2010) 116 (21): 3107.
https://doi.org/10.1182/blood.V116.21.3107.3107
Published: 2010
Journal Articles

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study

Sari Riihijarvi, Heidi Nyman, Harald Holte, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Eriksson Mikael, Sirpa Leppa
Journal: Blood
Blood (2010) 116 (21): 4142.
https://doi.org/10.1182/blood.V116.21.4142.4142
Published: 2010
Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Gilles Andre Salles, MD, PhD, John Catalano, MBBS, FRACP, FRCPA, Pierre Feugier, MD, PhD, Fritz C Offner, MD, PhD, Reda Bouabdallah, MD, Dolores Caballero, MD, Pauline Brice, MD, Lars Moller Pedersen, MD, Corinne Haioun, MD, David Belada, MD, Alain Delmer, MD, David Simpson, FRACP, FRCPA, MB, CHB, Herve Tilly, MD, Sirpa Leppa, MD, Pierre Soubeyran, MD, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, MSc, Christophe Fermé, MD, Maria Gomes da Silva, MD, Catherine Sebban, MD, Andrew Lister, MD, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, MD, Anne Sonet, MD, Armando Lopez-Guillermo, MD, John Francis Seymour, MBBS, FRACP, Ph, D, Luc Xerri, MD
Journal: Blood
Blood (2010) 116 (21): 1788.
https://doi.org/10.1182/blood.V116.21.1788.1788
Published: 2010
Journal Articles

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Clinical Trials & Observations
Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Flensburg, Jørgen Petersen, Nedjad Losic, John Radford
Journal: Blood
Blood (2008) 111 (12): 5486–5495.
https://doi.org/10.1182/blood-2007-10-117671
Published: 2008
Journal Articles

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Clinical Trials & Observations
Bertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, Ole Gadeberg, Henrik Fredriksen, Marinus H. J. van Oers, James Wooldridge, Janusz Kloczko, Jerzy Holowiecki, Andrzej Hellmann, Jan Walewski, Mimi Flensburg, Jørgen Petersen, Tadeusz Robak
Journal: Blood
Blood (2008) 111 (3): 1094–1100.
https://doi.org/10.1182/blood-2007-09-111781
Published: 2008
Journal Articles

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Clinical Trials & Observations
Martin Hutchings, Annika Loft, Mads Hansen, Lars Møller Pedersen, Thora Buhl, Jesper Jurlander, Simon Buus, Susanne Keiding, Francesco D'Amore, Anne-Marie Boesen, Anne Kiil Berthelsen, Lena Specht
Journal: Blood
Blood (2006) 107 (1): 52–59.
https://doi.org/10.1182/blood-2005-06-2252
Published: 2006